What is the prognosis of mantle cell lymphoma (MCL)?

Updated: Mar 15, 2019
  • Author: Muhammad Rashid Abbasi, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print
Answer

Answer

Mantle cell lymphoma (MCL) is associated with a poor prognosis. It exhibits a moderately aggressive course similar to that of intermediate-grade non-Hodgkin lymphoma (NHL). Unlike intermediate-grade lymphomas, it is rarely curable with currently available standard treatment.

Despite response rates of 50-70% with many regimens, MCL typically progresses after chemotherapy. Median time to treatment failure is less than 18 months. The median survival time is approximately 3 years (range, 2-5 y); the 10-year survival rate is only 5-10%.

Developing reliable prognostic markers has been difficult in the absence of better-standardized therapy. Younger age and limited disease are favorable prognostic features.

The blastoid variant, commonly associated with TP53 mutations, has been associated with a worse prognosis. Gene expression profile analysis identified MCL patient subsets with more than 5 years' difference in median survival, based on cyclin D1 and other proliferation signature genes.


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!